Status:
COMPLETED
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
Lead Sponsor:
University of Vermont
Conditions:
Pre-diabetes
Impaired Fasting Glucose
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.
Detailed Description
The investigators plan to conduct a prospective, randomized, double-blind, placebo-controlled parallel arm crossover study comparing insulin secretion and insulin resistance in subjects with impaired ...
Eligibility Criteria
Inclusion
- Men and women
- impaired fasting glucose
- We will stratify for weight and age.
Exclusion
- Known Type 2 DM
- Severe disease preventing participation in study
- On chronic steroids for any reason
- Already taking DPP-4 inhibitor
Key Trial Info
Start Date :
September 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01488279
Start Date
September 1 2012
End Date
December 1 2015
Last Update
March 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Vermont Clinical Research Center
South Burlington, Vermont, United States, 05403